Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach.

Autor:	Sussman M; Stratevi, LLC, Boston, MA 02111, USA; jennifer@stratevi.com., Benner J; Stratevi, LLC, Boston, MA 02111, USA; jennifer@stratevi.com., Mugwagwa T; Pfizer Ltd., Tadworth KT20 7NS, UK; tendai.mugwagwa@pfizer.com., Lee J; Stratevi, LLC, Santa Monica, CA 90401, USA; jackie@stratevi.com., Hung ST; Pfizer Inc., Taipei City 110, Taiwan; alice.hung@pfizer.com (S.-T.H.); ya-min.yang@pfizer.com (Y.-M.Y.)., Yang YM; Pfizer Inc., Taipei City 110, Taiwan; alice.hung@pfizer.com (S.-T.H.); ya-min.yang@pfizer.com (Y.-M.Y.)., Chen Y; Pfizer Investment Co., Ltd., Beijing 100010, China; yixi.chen@pfizer.com.
Jazyk:	angličtina
Zdroj:	Journal of market access & health policy [J Mark Access Health Policy] 2024 Nov 12; Vol. 12 (4), pp. 326-341. Date of Electronic Publication: 2024 Nov 12 (Print Publication: 2024).
DOI:	10.3390/jmahp12040026
Abstrakt:	Despite the observed clinical benefits of nirmatrelvir/ritonavir (NMV/r), it is uncertain whether Taiwan will continue covering NMV/r for high-risk individuals with mild-to-moderate coronavirus disease 2019 (COVID-19). This analysis assessed the impact of sustained utilization of NMV/r on COVID-19-associated healthcare resource utilization (HCRU) and mortality from the Taiwanese health authority perspective (THAP). A decision tree model estimated the incremental number of clinical events associated with NMV/r utilization over a 30-day period. Model results compared (1) a base case using current rates of NMV/r from the THAP, and (2) a hypothetical scenario assuming the current supply of NMV/r is not extended in Taiwan. NMV/r utilization rates included 80% and 0% in the base case and hypothetical scenario, respectively. Outcomes included the number of hospitalizations involving a general ward (GW) stay, intensive care unit (ICU) stay, and mechanical ventilation (MV) use, as well as the number of bed days, symptom days, and hospitalization deaths. Based on epidemiologic data, 150,255 patients with COVID-19 were eligible for treatment from the THAP. In the hypothetical scenario, HCRU increased by 175% compared to the base case, including increases in hospitalizations involving GW, ICU, and MV use (differences: 2067; 623; 591, respectively), bed days (difference: 51,521), symptom days (difference: 51,714), and deaths (difference: 480). Findings indicate that sustained utilization of NMV/r from the THAP reduces the clinical burden of mild-to-moderate COVID-19 through the reduced incidence of COVID-19-related HCRU and deaths. Competing Interests: Conflicts of InterestM.S., J.B. and J.L. are employees of Stratevi, LLC, which received funding to conduct this research. T.M., S.-T.H. and Y.-M.Y. are employees of Pfizer Inc., and Y.C. is an employee of Pfizer Investment Co., Ltd. T.M., Y.-M.Y. and Y.C. currently own or have previously owned company shares in Pfizer. This research was funded by Pfizer Inc. (© 2024 by the authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu